Further development of CAR-T cell therapy requires industry input

12-Sep-2018

Academic institutions globally are turning to immuno-oncology research to improve outcomes for young patients suffering from solid tumors

Further development of CAR-T cell therapy requires industry input

Seattle Children’s Hospital (SCH) has recently initiated STRIvE-01 study of two chimeric antigen receptor (CAR)-T cell therapies in young people ages 1–26, with relapsed or refractory (R/R) non-central nervous system epidermal growth factor receptor (EGFR) positive solid tumors.

The Phase I trial will investigate one CAR-T cell product that targets both EGFR and B-cell specific target (CD19) and another that only targets EGFR.

According to data and analytics company, GlobalData, if data from the SCH’s new study are positive, collaboration with industry will likely be required to support further clinical development and commercialisation of anti-EGFR/CD19 CAR-T cell therapy.

So far, the success of CAR-T cell therapy has been limited to haematological malignancies, with unprecedented efficacy being demonstrated. However, CAR-T cell expansion rates in solid tumors have remained low and appear to be a limiting factor for the therapy’s efficacy.

To date, Merck’s Keytruda (pembrolizumab) is the only therapy to have received a tumour-agnostic approval from the FDA for any solid tumour that is either microsatellite instability-high or mismatch repair deficient, but the industry is increasingly moving towards tissue-agnostic development.

Of the 25 ongoing clinical trials evaluating EGFR targeted CAR-T cells in solid tumours, this is the only study in which the CAR-T product is also engineered to target CD19. Targeting CD19-positive B-cells is hypothesised to enhance T-cell expansion by promoting an immune response and therefore aims to increase the efficacy of the CAR-T cell therapy.

Chloé Thépaut, Senior Healthcare Analyst at GlobalData, said: “The SCH’s approach of using a B-cell target to enhance immune response could overcome this major hurdle in the development of CAR-T cell therapies in solid tumors. Although a high cure rate can be achieved in most solid tumors, except for brain tumors, with other treatments such as surgery, long-term survival is lower for R/R patients.”

The SCH has adopted a scientifically rational approach that could overcome the difficulties of ensuring CAR-T cell expansion and enhance efficacy in solid tumors, thereby addressing a substantial untapped opportunity. The SCH’s Phase I/II trial will include patients with multiple EGFR positive tumour types, which could lead to a significant commercial opportunity for a broad label, if pan tumour efficacy is demonstrated.

Sign up for your free email newsletter

Thépaut concluded: “Many unmet needs remain for young patients with solid tumors, and academic institutions globally are turning to immuno-oncology research to improve outcomes. If data from the SCH’s new study are positive, collaboration with industry will likely be required to support further clinical development and commercialization of anti-EGFR/CD19 CAR-T cell therapy.”

Companies

Featured Companies

Related Content

Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Commercial opportunities for emerging infectious diseases vaccine developers
Commercial opportunities for emerging infectious diseases vaccine developers
Global atopic dermatitis market set to reach $18.3 billion by 2027
Global atopic dermatitis market set to reach $18.3 billion by 2027
Pfizer’s palbociclib is the top breast cancer drug used in clinical trials initiated in 2018
Pfizer’s palbociclib is the top breast cancer drug used in clinical trials initiated in 2018
Pharma companies may miss crucial EU drug packaging deadline with a no-deal Brexit
Pharma companies may miss crucial EU drug packaging deadline with a no-deal Brexit
Global chronic lymphocytic leukemia market set to reach $9.2bn by 2027
Global chronic lymphocytic leukemia market set to reach $9.2bn by 2027
Non-small cell lung cancer market projected to be worth $14.6 billion by 2024
Non-small cell lung cancer market projected to be worth $14.6 billion by 2024
Global glioblastoma market set to reach $1.4bn by 2027
Global glioblastoma market set to reach $1.4bn by 2027
Pancreatic cancer treatment heads in promising direction, says GlobalData
Pancreatic cancer treatment heads in promising direction, says GlobalData
Patients could lose out on life-saving treatments
Patients could lose out on life-saving treatments